Spotlight Innovation Inc. (OTC Pink: STLT) engages in the identification and acquisition of cancer drugs and treatment therapies. Shares of the cancer treatment company are rallying 68% during early morning trading on Tuesday, August 30, 2016. Over the past three months, Spotlight Innovation Inc has seen average daily volume of 10,328 shares. However, nearly 81,050 or dollar volume of $80,240 has already exchanged hands during early morning trading Tuesday.
Spotlight Innovation Inc is seeing shares rally today after management announced that a landmark study concerning to classes of compounds to tackle the Zika virus. Professor Hengli Tang was one of the co-authors of the study that took a look at compounds that protect Zika virus neural cells from programmable cell death. In addition, the other study took a look at how to inhibit Zika virus reproduction and replication. The landmark study was published in Nature Medicine. Here is the press release detailing of the study:
Spotlight Innovation Inc Press Release:
WEST DES MOINES, Iowa, Aug. 30, 2016 /PRNewswire/ — Spotlight Innovation Inc. (STLT) announced today that Prof. Hengli Tang has co-authored a study1, published in Nature Medicine on August 29, 2016, reporting two classes of compounds: one that protects Zika virus-infected neural cells from programmed cell death (“apoptosis”) and another that directly inhibits Zika virus replication. According to the study, when used in combination, compounds from the two classes enhanced the neuroprotective effect.
Spotlight Innovation Inc. identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress.
Since the resurgence of Zika over a year ago, efforts to combat the virus have focused largely on preventing infection through vaccine development, mosquito control measures and public health education. The availability of anti-Zika therapeutics could provide physicians with tools to treat patients who have already been infected. Funding provided by Spotlight Innovation under a Sponsored Research Agreement with Florida State University will enable Prof. Tang and his collaborators to expand on their discoveries and to accelerate the development of safe and effective drugs to treat patients infected with Zika.
Geoffrey Laff, Ph.D., Spotlight Innovation’s Senior Vice President of Business Development, commented, “Prof. Tang’s important work reinforces our long-standing conviction that he and his collaborators will significantly advance the field of anti-Zika virus drug development.”
In a recent publication2, Prof. Tang and his collaborators demonstrated that Zika virus can infect and replicate within human embryonic cortical neural progenitor cells. Zika infection in pregnant women can cause neurological birth defects, including microcephaly, a condition in which a child is born with an abnormally small head as a result of incomplete brain development.
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.